Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt : Expansion of PathFlow® COVID-19 lateral flow test portfolio

06/29/2021 | 02:20am EDT

Paris, France and Camberley, UK - 29 June 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is to launch two PathFlow® COVID-19 antigen lateral flow tests (LFTs) to strengthen the Company's COVID-19 portfolio and to pursue significant new market opportunities, especially in point-of-care (POC) settings. The Company will initially target private market opportunities for these LFTs via its existing distribution network.

http://novacyt.com/wp-content/uploads/2021/06/Novacyt-Expansion-of-PathFlow®-COVID-19-final.pdf

Disclaimer

Novacyt SA published this content on 29 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 June 2021 06:19:34 UTC.


© Publicnow 2021
All news about NOVACYT
09/16FTSE 100 Rises on Speculation over UK's Travel Restrictions Removal
DJ
09/16GLOBAL MARKETS LIVE : Thales, Nestlé, Evergrande, AMC, Walmart...
09/16FTSE Rises, THG Shares Fall After 1st Half Loss as Shake-Up Looms
DJ
09/16NOVACYT : Dispute With UK Health Department Threatens To Wipe Out H1 Profit
MT
09/16FTSE Rises, Ashtead Gains After 1Q Profit Boost, Guidance Increase
DJ
09/16Novacyt Says Covid-19 Contract Dispute with UK Health Department Continues
DJ
09/16Novacyt to Revise Down 1st Half Revenue Due to UK Covid-19 Contract Dispute -..
DJ
09/16NOVACYT : Proposed accounting treatment of ongoing DHSC dispute in 2021 interim ..
PU
09/13NOVACYT : AGM voting
PU
09/08NOVACYT : Company's activity during FY20
PU
More news
Financials
Sales 2021 112 M 132 M 132 M
Net income 2021 70,0 M 82,4 M 82,4 M
Net cash 2021 90,4 M 106 M 106 M
P/E ratio 2021 4,37x
Yield 2021 -
Capitalization 269 M 316 M 316 M
EV / Sales 2021 1,60x
EV / Sales 2022 0,91x
Nbr of Employees 174
Free-Float 99,3%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 3,81 €
Average target price 8,88 €
Spread / Average Target 133%
EPS Revisions
Managers and Directors
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Reginald A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-61.17%316
MODERNA, INC.321.80%177 867
BIONTECH SE357.13%90 003
GILEAD SCIENCES, INC.22.43%89 434
REGENERON PHARMACEUTICALS35.20%67 910
WUXI APPTEC CO., LTD.28.41%65 728